Bala Nn Rao Attili

Director - Oncology Safety Sciences AstraZeneca

Seminars

Tuesday 11th November 2025
Elucidating Radiobiological Mechanisms of Cytotoxicity & Immune Modulation to Inform Selection of Optimal Radiopharmaceutical Targets
11:00 am
  • Investigating the cellular and molecular mechanisms underlying radiopharmaceutical-induced cell death to optimise therapeutic outcomes
  • Exploring how radiopharmaceuticals interact with the immune system to enhance anti-tumour immunity and reduce resistance
  • Leveraging insights from radiobiology and immune modulation to identify and select optimal radiopharmaceutical targets for improved tumour control and reduced toxicity
Monday 10th November 2025
Designing Safer Radiopharmaceuticals – Balancing Innovation with Toxicity Management
1:00 pm

As radiopharmaceutical therapies advance, ensuring patient safety remains paramount. This workshop offers a comprehensive overview of designing novel radiopharmaceuticals with an emphasis on minimising toxicity. We’ll explore the intricacies of molecular designrom targeting moieties to payloads and discuss strategies to mitigate associated toxicities.

  • Designing safer tumour-targeted in situ RadioIMmunoStimulants (RIMS) for metastaticcastration resistant prostate cancer
  • Disease Biology Insights: Understanding diseasespecific biology to inform safer drug design
  • Optimising pharmacokinetics and safety to improve radiation exposure
  • Toxicity Exploration: Identifying common toxicities in radiopharmaceuticals and strategies to avoid them across different modalities
Bala Atilli, Director - Oncology Safety Sciences, AstraZeneca